BioMelbourne Network Progressing BioIndustry

10th June BioBreakfast - The Current and Future Outlook for Cell Therapies
To be held at the Peter MacCallum Cancer Centre More

Victorian BioPortal

Looking for Something?

The Victorian BioPortal is the largest online search engine for biotechnology in Victorian with over 2,000 individual listings.

Start your search now

BioMelbourne Network

The Building Global Bridges program provides grants of between $100,000 & $500,000 to Victorian life science companies to develop partnerships with Massachusetts companies in late stage life sciences R&D projects. The program helps Victorian innovation to accelerate, access expertise, develop skills & better reach global markets and international investors. Applications close 17 September 2013.

Building Global Bridges

New Awards Recognise Women in Leadership in Biotech, Medtech and Healthcare Technology

22 May 2015.  Australian women do comparatively well in biotechnology, medtech and health care technology – with 11.1% of companies in the sector in the ASX 200 having female executive key management personnel and 11.9% in the ASX 500.However, in recognition that these figures need to improve and to honor outstanding women in the sector, The BioMelbourne Network will, this Friday, announce its ... read more…

dorsaVi Secures London Underground and VINCI Construction as its First UK Occupational Health and Safety Customers

21 May 2015.  Medical device company dorsaVi Ltd (ASX: DVL) today announced the signing of its first two UK-based occupational health and safety (OHS) customers: London Underground and VINCI Construction UK Ltd. The agreements with the two industry leaders represent a major milestone for the Australian company who formally introduced its innovative OHS technology, ViSafe™, into the UK market in... read more…

Starpharma - Spare Lab/Office Space

21 May 2015.  Starpharma has some surplus lab and office space at their new premises in Abbotsford. Good lab space is certainly hard to find so hopefully it would be of benefit to all of you. Read the brochure below for more details: read more…

Gordagen Wins High Court of Malaysia Judgement for Breach of Confidentiality

20 May 2015.  Gordagen Pharmaceuticals Pty. Ltd., a private Australian company commercialising evidence-based dietary supplements and pharmaceuticals, today announced that the High Court of Malaysia has issued a judgement against Ms. Nurul Athirah binti Sufi (Ms. Athirah), a former employee of the Company. Ms. Athirah was represented to Gordagen in January 2014, as a chartered accountant with a... read more…

INV102 (Oral Nadolol) Data Presented to American Thoracic Society Meeting in Denver, Colorado

19 May 2015.  Australian respiratory technology company Invion Limited (ASX: IVX) has presented data from a trial of lead compound INV102 (oral nadolol) to international medical experts at a prestigious US pulmonary conference.Trial investigators have shown delegates at the American Thoracic Society (ATS) meeting that an ongoing Phase 2 study of Invion’s INV102 as an aid to smoking cessation ha... read more…

Your invitation to the Industry Growth Centre Consultations for the Medical Technologies and Pharmaceuticals Sector

18 May 2015.  Dr Bronwyn Evans, Chair of the Medical Technologies and Pharmaceuticals Industry Growth Centre would like to invite you to participate in a range of consultations designed to shape the future of the sector. Dr Evans has scheduled a range of opportunities for interested participants to share their views about how the productivity and competitiveness of the sector can be significan... read more…

Australia’s Minister for Industry and Science Declares Trajan is “Leading the Way” in World Class, Australian-Based Advanced Manufacturing

15 May 2015.  Pioneering collaboration and world-class products meeting global standards – these were the take-home impressions of the Australian Minister for Industry and Science, Ian Macfarlane, during a special visit to Trajan Scientific and Medical (Trajan) global headquarters facilitated by Mr Michael Sukkar, Federal Member for Deakin, Victoria.Trajan exports 98 per cent of its products th... read more…

Phosphagenics: Oxymorphone Patch Program Update

14 May 2015.  Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), has completed a review of its TPM®/Oxymorphone patch development program using specialist external consultants. On the back of previously announced clinical trial results showing that the TPM®/Oxymorphone patch can deliver blood levels of oxymorphone corresponding to the therapeutic levels seen with ... read more…

Sun Biomedical Limited to Aquire Dimerix Bioscience

13 May 2015.   The Board of Sun Biomedical Ltd, an Australian biotechnology company, is pleased to announce that the Company has signed an implementation agreement to acquire 100% of Dimerix Bioscience Ltd (Dimerix), a public unlisted clinical stage drug discovery and development company, based in Melbourne. Dimerix’s lead clinical program is a Phase 2 study in patients with Chronic K... read more…

Nexvet Appoints Dr. Jurgen Horn as Chief Product Development Officer

11 May 2015.  Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced it has appointed former Elanco and Novartis Animal Health executive Dr. Jürgen Horn as its new Chief Product Development Officer. Dr. Horn will commence his role at Nexvet in August 2015. Dr. Horn most recently served as Senior Director of Global Innovation Strategy at Elanco, one of the wor... read more…

OPT-302 Data Presented at Two Major Ophthalmology Conferences

7 May 2015.  Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) reports that  Dr Kameran Lashkari of Schepens Eye Research Institute/Massachusetts Eye & Ear at Harvard Medical School presented preclinical data overnight at the annual ARVO  conference in Denver demonstrating efficacy with Circadian’s targeted therapy OPT-302 (VGX-300). The data demonstrates OPT-302 reduced blood vessel growth... read more…

Penthrox successfully completes its Decentralised Regulatory Approval Procedure in Europe

6 May 2015.  Medical Developments International Limited (ASX: MVP) is delighted to announce that the Medicine and Healthcare products Regulatory Agency (“MHRA”) has issued the Final Assessment Report with the support of France, Belgium and Ireland authorities noting all outstanding issues pursuant to the Decentralised Procedure have been successfully resolved and Penthrox is approvable.MVP now ... read more…

Trade Events Program announced for BIO 2015

30 April 2015.  A terrific announcement from Innovation Minister Adem Somyurek this week! The Victorian Government’s Trade Event Program will provide up to $2000 for companies to travel to international trade events, including BIO 2015. I’ve already been talking with one biotech start-up who are now seriously considering going to BIO on the basis of this announcement, whereas they wouldn’t hav... read more…

Invion Appoints Mr Brett Heading as Chairman After Dr Ralph Craven Retires from Board of Directors

29 April 2015.  Following Dr Ralph Craven’s retirement as Chairman after three and a half years, Australian drug development company Invion Limited (ASX: IVX) has appointed well known corporate lawyer, Brett Heading, as Chairman of the Board of Directors.Invion Managing Director and Chief Executive Officer Dr Greg Collier said: “The entire Board and staff of Invion are immensely grateful to Dr ... read more…

IHearYou® ‘Self fit’ Hearing Systerm receives Good Design® selection for 2015

28 April 2015.  IHearYou® ‘self-fit’ Hearing System has been shortlisted for the coveted Good Design Awards, Australia’s oldest and most prestigious award for design and innovation with its origins dating back to 1958. The Awards showcase superior examples of good design across a broad range of industries and design disciplines. There are seven main categories for the awards and 25 sub-categori... read more…

Invion Limited $4.1 Million Entitlement Offer Fully Subscribed Further $1.3 Million Placement Completed

22 April 2015.  On 20 March 2015, Invion Limited (ASX: IVX) announced a 2 for 7, fully underwritten, non-renounceable Entitlement Offer for ordinary shares at an offer price of $0.025 (Entitlement Offer) to raise approximately $4.1 million, following on from its successful placement at the same price per share for a total capital raise of $5.0 million. Invion today is pleased to announce that t... read more…

Phosphagenics Initiates Oxycodone Patch Dosing in Phase 2 Clinical Trial

17 April 2015.  Australian drug delivery company Phosphagenics Limited (ASX:POH; OTCQX:PPGNY) has commenced dosing in its Phase 2 TPM®/Oxycodone patch trial (POH 035-13). Study POH 035-13 is a double-blind, randomised, cross-over Phase 2 clinical trial investigating the safety and efficacy of Phosphagenics’ TPM®/Oxycodone patch in up to 28 patients suffering post herpetic neuralgia (PHN).   Re... read more…

FDA Confirms Change of Ownership of 23 US Generic Drugs and IDT Successfully Manufactures First Batch of Tablets

13 April 2015.  IDT Australia Limited (IDT.AX) announces that the US Food and Drug Administration (FDA) has confirmed receipt of the change of ownership letters formally transferring ownership of the 23 generic drug products to IDT.   Formalising change of ownership is a process whereby the vendor and the purchaser both submit correspondence informing the FDA that the transfer of a drug regis... read more…

Phosphagenics Appoints Three New Directors

13 April 2015.  Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), announces that it has appointed three new directors to The Board. The new directors include Dr Greg Collier, Mr Peter Lankau and the Company’s recently appointed CEO, Dr Ross Murdoch.Dr Greg Collier is currently the CEO of ASX listed company Invion Ltd, and has more than 20 years’ experience spanni... read more…

Trajan and University of Tasmania Secure Top Postdoctoral Fellows for ASTech

27 March 2015.  Trajan Scientific and Medical (Trajan) and University of Tasmania (UTAS) are delighted to secure three top scientists to oversee innovative research programs at ASTech, the ARC Training Centre for Portable Analytical Separation Technologies, supported by the Australian Research Council (ARC).ASTech is a collaboration between Trajan and UTAS combining industry knowledge and resea... read more…